Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals